Waiting for the right time is seductive.
Our mind tricks us into thinking doing something now is hard but if we wait it will get easier.
Most of the time, waiting only makes things harder.
The right time is now.
Interesting look back as FDA approves 100th mAb
- About half the approved mAbs are for one of 8 targets.
- Though 1st approval in 1980s, majority in 2010s i.e., ~30 years after
What does this say about today's new modalities? #biotwitter#Biotechnology
https://t.co/m6el4Ev0vO
A good reading strategy is to be willing to try any book that looks even slightly interesting but be ruthless about quitting books that aren't working for you, even after a page or two.
Wide funnel, tight filter.
New modality drugs are making it to market at an increasing clip. ~30 in last 5 years, ~50 in registrational trials. Different factors for different modalities, but some of the hurdles are the same. @biocentury. https://t.co/Luz0zSiRtN
Read how the pursuit of self sufficiency morphed into investment licensing, import controls, small-scale industries reservation and price and distribution controls, holding the Indian economy back for four decades.
From 2016 to 2020, the market capitalization of publicly listed Chinese companies developing innovative drugs rose from $1 billion to $217 billion, according to McKinsey. In 2019, the first China-developed cancer treatment was approved in the U.S.
https://t.co/ovWtcDXyom